Key Highlights
COVID-19 has brought the healthcare and life sciences industry under an unprecedented spotlight. Companies have to supply critical medical products and drugs to support hospitals and patients, while also looking into developing new drugs and vaccines. Data security and confidentiality is core to this industry’s research and product development. As the strategic partner of a Fortune 500 pharmaceutical company, the COVID-19 lock-down posed a unique challenge for WNS. Historically, a Work-from-Home (WFH) model had never been allowed or attempted, and thus, a contracted business continuity plan was unavailable. At the same time, business continuity could not be compromised across key areas such as research and development, and business intelligence.